MANNKIND CORP Notes Payable, Current
MANNKIND CORP (MNKD) had Notes Payable, Current of $45.38 million as of 2020-09-30, per its 10-Q filed 2020-11-04.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt, Current Maturities
us-gaap:NotesPayableCurrent · last filed 2021-02-25
- 2020-09-30: Notes Payable, Current $45.38M.
- 2020-06-30: Notes Payable, Current $5.39M.
- 2020-03-31: Notes Payable, Current $5.10M.
- 2019-12-31: Notes Payable, Current $5.03M.
| Period end | Notes Payable, Current |
|---|---|
| 2020-09-30 | $45.38M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $5.39M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $5.10M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $5.03M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |